YAQRIT

Liver cirrhosis kills more than a million people a year. More than 650 million people around the world suffer from chronic liver disease, costing economies €15.8 billion annually. Yaqrit Limited is developing a family of liver disease treatments that will transform the lives of these patients. Today, there are few options for treatment. Antibiotics and laxatives, which target gut bacteria and bacterial products, or a liver transplant are the standards of care. The drawbacks of widespread antibiotic use are well-known, and waiting lists for transplants are long – in the UK, for example, 30% of patients on the waiting list have been there for more than two years.